News

A study found that oral physiological changes from allergen exposure in Oral Allergy Syndrome do not alter Anaphylm’s pharmacokinetic or pharmacodynamic profiles.

There was a 79% relative reduction in annualized asthma exacerbation rate in the 6 months after starting treatment compared with the prior 6 months.

At AAAAI 2025, HCPLive spoke with Mahdavinia about how climate change impacts allergies.

HCPLive spoke with Cohen about how patients with a peanut allergy responded to oral immunotherapy with autoclaved peanuts.

Sabato discussed how research in the field will inform how to best utilize novel therapies for indolent systemic mastocytosis now that a disease-modifying therapy is available.

HCPLive spoke with Nyenhuis at AAAAI 2025 about ways to help patients with allergies despite the growing pollen seasons.

Our top 5 headlines include an FDA approval, a pair of submissions, data from AAAAI 2025, and more!

Alexis discussed the latest research in the field and new management strategies for children with atopic dermatitis.

HCPLive spoke with Warren at AAAAI 2025 about a pilot study showing allergen-free food subscriptions reduced healthcare use but lacked significance.

This FDA News Month in Review provides a round-up of regulatory decisions from February 2025.

Stallergenes Greer announced that Palforzia is now available for children under 4 years old with a peanut allergy, which follows the extended indication approval in July 2024.

Chovatiya discussed his talk at the 2025 AAAAI/WAO Joint Congress.

The guidance is intended to inform the transition to outpatient care for patients with AKI-D and help care teams identify early signs of recovery.

Kernizan discusses winning the 2024 Society for Pediatric Dermatology Medical Student Mentorship Award and getting into pediatric dermatology as a student.

New data from the REDUCE-IT trial suggests icosapent ethyl offers benefit even among those with LDL-C less than 55 mg/dL.

Fidanacogene elaparvovec was approved under the name Beqvez in April 2024.

Stine explains key components of a new multidisciplinary MASLD care model and how it improves upon preexisting models.

Dupilumab improved R5–R20 and AX compared to placebo, possibly explaining improvements in disease control.

Finerenone reduces outpatient worsening HF in patients with mildly reduced or preserved ejection fraction in a secondary analysis of FINEARTS-HF.

A study at AAAAI 2025 found that dupilumab led to a 73.5% reduction in IgE levels at 24 months.

In this analysis, investigators demonstrated that risankizumab led to improvements in palmoplantar pustulosis (PPP) that continued through to Week 68.

In adolescents and young adults, gastrointestinal complications from alcohol are increasing at greater rates than other organ systems.

A study at AAAAI 2025 found that monitoring transepidermal water loss during oral food challenges reduced anaphylaxis rates and epinephrine use in children.

These data point to the necessity of quality and usability when using smartphone photographs of skin conditions in emergency departments.

In this quiz, we test your knowledge of the latest guideline recommendations for aspirin therapy in AERD.

Mukkamala also discussed the importance of expanding non-opioid pain relief options.

Stine explains the continued need for diet and exercise in MASH and the importance of a multidisciplinary approach to treating these patients.

In this interview, Druskovich highlights her experiences being mentored through the Society for Pediatric Dermatology’s Medical Student Mentorship Award.